|
|
|
| |
 |
|
|
|
推薦指數：
|
|
- 內容介紹
|
Renal and Adrenal Tumors - Biology and management
Edited by Arie Belldegrun, Roy and Carol Doumani Chair in Urologic Oncology, Professor of Urology, Chief, Division of Urologic Oncology, Director, Urologic Research, UCLA School of Medicine
-19-850822-0
Publication date: 6 March 2003
634 pages, numerous figures, tables and halftones, 276 mm x 215mm
In the past decade there has been an explosion of far-reaching developments in the biological and physical sciences relevant to cancer. The incidence and mortality from renal cell carcinoma has continuously risen over the past 50 years. Despite this, survival for patients has notably improved and great strides have been made in the management of patients with renal cell carcinoma. Our understanding of the natural history of renal cell carcinoma, the role of nephrectomy, the benefits of immunotherapy and the possibilities of new technologies are evolving and are being integrated with advances in classification and staging.
This book provides a comprehensive source of information on renal and adrenal tumors that will be of practical interest for students, residents, physicians, and researchers alike. It reviews comprehensively the current understanding of the biology, pathophysiology and urological oncology of the disease, looking at the clinical problems and potential solutions including chapters on both the scientific and clinical principles. Fully illustrated, the book emphasises new advances in molecular biology, pathogenesis, detection and experimental therapeutics and focuses on new developments in clinical research. An international team of recognized of experts have been brought together to provide historical perspectives, an overview of basic facts, and an assessment and exploration of the newer developments in our understanding of the clinical, genetic, and molecular aspects of these diseases. The book clearly distinguishes what is generally agreed upon from what is still controversial, giving both sides equal treatment.
The primary market will include medical and clinical oncologists, urologists and trainee urologists, clinical pathologists, nephrologists and research workers in renal cancer
|
|
|
其他相關書藉
[ 
[ 